A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy
A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.
Inclusion Criteria:
Exclusion Criteria:
Is a female patient of childbearing potential and any of the following is true:
Has a study eye with a history of cataract surgery within 90 days of Visit 1
Meet any other exclusion criteria outlined in clinical study protocol
Cleveland, Ohio 44106, United States